Participated · Series D · Sep 2025

Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to precisely target disease pathology in autoimmune and inflammatory diseases. Since its founding in 2021, the company has built comprehensive drug discovery and development capabilities and advanced an internally discovered program through multiple clinical milestones. Odyssey has nominated multiple development candidates and established collaborations with pharmaceutical leaders and biotech innovators. Its portfolio includes internally discovered clinical and preclinical candidates intended to induce deep and durable remission across several inflammatory diseases with unmet need. The company plans to advance these programs toward important clinical milestones and translate scientific efforts into patient benefit. Odyssey recently completed a major financing to support progression of its clinical pipeline. Odyssey Therapeutics has built a discovery and development platform that merges computational and experimental technologies to identify modality-agnostic drug targets with high clinical potential. From its Boston headquarters, the company has advanced multiple programs from ideation to a portfolio of high-value product candidates within about two years of founding in late 2021. Odyssey is focused on bringing immunology and oncology therapeutics into clinical development, with several molecules that could enter the clinic in the next 12 months. Proceeds from financing will support advancement of multiple programs into clinical studies and continued investment in discovery to build a sustainable model for therapeutic innovation. The company emphasizes a capital-efficient model and aims to deliver safe and effective precision medicines to patients with serious diseases. Leadership includes founder and CEO Gary D. Glick, Ph.D., and an experienced board guiding clinical and company-building strategy. Odyssey Therapeutics, based in Boston, raised $168M in a Series B funding round led by General Catalyst. The round included participation from Fidelity Management & Research Company, T. Rowe Price Associates, GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, The Healthcare Innovation Investment Fund LLC, OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures and Creacion Ventures. The company intends to use the funds to advance its portfolio of precision immunomodulators and oncology medicines. Its immunology and oncology portfolio encompasses eight declared programs initially focused on small molecule and protein therapeutics. Odyssey is building a discovery engine that integrates artificial intelligence and machine learning for molecular design, a chemistry platform encompassing proprietary covalent libraries targeting multiple amino acids, molecular glues and natural products, and a functional genomics platform for novel target discovery. Gary D. Glick, Ph.D. is Founder and Chief Executive Officer. Odyssey Therapeutics develops next-generation precision immunomodulators and oncology medicines using a discovery platform that combines target biology, medicinal and structural chemistry, physics-based molecular simulations, and AI/machine learning. The company was founded by Gary D. Glick, Ph.D., and is led by a team with a track record that includes helping bring more than 20 drugs to market. Odyssey intends to advance multiple pipeline programs and expand its discovery platform to broaden the druggable genome. Financially, the company completed a large Series A financing (see deal details). Odyssey is headquartered in Boston, with labs there, and is expanding its team to more than 90 scientists and staff. The company emphasizes selecting targets and therapeutic modalities aimed at maximizing clinical impact.

Participated · Series A · Jan 2022

Ceptur Therapeutics is a pre-clinical biotechnology company developing targeted oligonucleotide therapeutics using its proprietary U1 Adaptor technology. U1 Adaptors are bivalent oligonucleotides that engage sequence-specific mRNA and the U1 small nuclear ribonucleoprotein to control gene expression at the pre-mRNA level within the nucleus. The modality is positioned to address difficult targets by co-opting a ubiquitous regulator of transcription and splicing. Ceptur in-licensed and expanded its foundational U1 Adaptor IP portfolio in 2021 and has recruited a scientific advisory board of academic and industry leaders in oligonucleotide therapeutics. The company is headquartered in Hillsborough, New Jersey. It recently completed a $75M Series A financing to advance its broad discovery pipeline of differentiated genetic medicines.

Led · Series A · Jun 2021

Kurome Therapeutics is a preclinical-stage company developing novel therapies that target adaptive resistance mechanisms in cancer while inhibiting disease-modifying genes. Its lead programs are combined IRAK1/4 and panFLT3 inhibitors designed to target cancer cells that have co-opted IRAK1/4-mediated immune signaling. The company says the Series A financing will support preclinical advancement to substantially de-risk compound selection and to identify a first development candidate ahead of an IND filing. Initial clinical focus is improving outcomes in poor-prognosis acute myeloid leukemia (AML), with planned expansion to other hematopoietic cancers including myelodysplastic syndromes (MDS) and certain solid tumors with dysregulated IRAK1/4 signaling. Kurome was launched in 2020 based on research at Cincinnati Children’s Hospital Medical Center in collaboration with the NIH National Center for Advancing Translational Sciences. Jan Rosenbaum serves as Chief Executive Officer and Chief Scientific Officer, and the scientific foundation for the biology under study was discovered by Daniel Starczynowski, PhD.

Participated · Series C · May 2021

Hummingbird Bioscience discovers and engineers precision therapeutics using a proprietary Rational Antibody Discovery platform to target optimal yet elusive epitopes. The company is advancing a pipeline of first- and best-in-class therapies in oncology and autoimmunity, including clinical-stage assets. Lead programs include HMBD-001, a HER3 antibody for NRG1-fusion and HER3-driven tumors, and HMBD-002, a first-in-class anti‑VISTA neutralizing antibody for advanced solid tumors. The company is also progressing HMBD-009, a BCMA‑TACI dual‑specific T cell engager, as part of its next‑generation pipeline. Hummingbird collaborates with global partners in academia and industry to advance its programs. Piers Ingram is CEO and co-founder. Hummingbird Bioscience is a biotherapeutics company developing antibody-based treatments for cancer and other diseases. The company has published data on two oncology antibodies and expects to submit regulatory filings to start Phase 1 studies in the second half of this year. It said the new funding will be used to accelerate those therapies into clinical trials and to expand research and development for its early-stage pipeline. Hummingbird has offices in Singapore, Houston and South San Francisco and strategic collaborations with Cancer Research UK and Amgen. It was previously awarded a product development grant from the Cancer Prevention and Research Institute of Texas. Financially, the company has now raised $65 million in total, with the Series B reaching $25 million after the recent extension. Hummingbird Bioscience is a biotherapeutics company developing precision antibody therapeutics using a proprietary rational antibody discovery platform and systems biology expertise. It is building a broad pipeline of first- and best-in-class drug candidates across multiple indications, including HMBD-001 (anti-HER3) and HMBD-002 (anti-VISTA) for cancer. The company raised US$19M in a Series B and intends to use the funds to discover new disease targets, expand its antibody pipeline, and accelerate co-discovery projects under a multi-target collaboration with Amgen. HMBD-001 and HMBD-002 are expected to enter first-in-human clinical trials following regulatory submissions in the second half of 2020. The Series B was co-led by Mirae Asset Venture Investment and GNTech Venture Capital, with participation from existing investors Heritas Capital and Seeds Capital and new investors including Delian Capital, Mirae Asset Capital, DAValue-GiltEdge, HB Investment, Wooshin Venture Investment, and Kiwoom Investment-Shinhan Capital. Led by CEO and co-founder Dr. Piers Ingram, the company has strategic collaborations with Cancer Research UK and Amgen and is based in Singapore, Houston (Texas) and South San Francisco (California).